Risk factors associated with seropositivity 3 weeks after COVID-19 mRNA vaccination in solid organ transplant recipients
| Variable | Univariable analysis | Multivariable analysis |
|||
|---|---|---|---|---|---|
| OR (95% CI) | P-value | Adjusted OR (95% CI) | P-value | ||
| Age ≥60 yr | 0.81 (0.24–3.25) | 0.75 | - | - | |
| Male sex | 1.20 (0.39–3.53) | 0.75 | - | - | |
| GFR (mL/min/1.73 m2) | |||||
| ≥30 & <45 | 0.48 (0.11–2.46) | 0.33 | - | - | |
| 45≤ | Reference | Reference | - | - | |
| Years from transplant | |||||
| ≤3 | Reference | Reference | Reference | Reference | |
| >3 | 6.43 (1.64–42.9) | 0.02 | 4.18 (0.66–36.73) | 0.15 | |
| ABO-incompatible transplant | 0.81 (0.24–3.25) | 0.75 | - | - | |
| Rituximab use within 1 yr | 0.24 (0.06–0.97) | 0.04 | 1.19 (0.16–10.57) | 0.87 | |
| High-dose steroid use within 1 yr | 0.36 (0.12–1.06) | 0.07 | 1.37 (0.28–7.39) | 0.70 | |
| Basiliximab or anti-thymocyte globulin use within 1 yr | 0.19 (0.06–0.59) | 0.004 | 0.56 (0.10–2.92) | 0.49 | |
| Maintenance immunosuppressant | |||||
| Tacrolimus serum concentration ≥8 ng/mL | 1.02 (0.22–7.24) | 0.98 | - | - | |
| Steroid | 0.26 (0.08–0.86) | 0.03 | 0.37 (0.07–1.98) | 0.24 | |
| Mycophenolic acid | 0.06 (0.00–0.35) | 0.01 | 0.06 (0.00–0.39) | 0.02 | |
| mTOR inhibitor | 1.88 (0.45-12.84) | 0.44 | - | - | |
| Vaccination regimen | |||||
| Heterologous booster | Reference | Reference | - | - | |
| Homologous booster | 1.18 (0.24–4.49) | 0.82 | - | - | |
| Booster vaccine | |||||
| mRNA-1273 | Reference | Reference | - | - | |
| BNT162b2 | 2.80 (0.87–8.80) | 0.08 | 3.45 (0.72–17.69) | 0.12 | |
| Interval between second and third doses >3 mo | 1.29 (0.06-10.88) | 0.83 | - | - | |
COVID-19, coronavirus disease 2019; OR, odds ratio; CI, confidence interval; GFR, glomerular filtration rate; mTOR, mammalian target of rapamycin.
a)Tjur’s R2=0.30.